Turnstone Biologics
TSBX
TSBX was delisted on the 8th of August, 2025.
28 hedge funds and large institutions have $5.51M invested in Turnstone Biologics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
17% more funds holding
Funds holding: 24 → 28 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
1.5% less ownership
Funds ownership: 49.47% → 47.97% (-1.5%)
14% less capital invested
Capital invested by funds: $6.37M → $5.51M (-$864K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$33.3K |
| 2 |
Citigroup
New York
|
+$30.3K |
| 3 |
Renaissance Technologies
New York
|
+$11.8K |
| 4 |
Goldman Sachs
New York
|
+$10.1K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$7.53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
-$253K |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$27.8K |
| 3 |
Millennium Management
New York
|
-$14.5K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$9.98K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$9.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $2.34K | -$642 | -1,300 | -22% |
|
27
JP Morgan Chase
New York
| $98 | +$20 | +41 | +26% |
|
28
UBS Group
Zurich,
Switzerland
| $35 | -$5.22K | -10,572 | -99% |
|
|
ECM
29
ExodusPoint Capital Management
New York
| – | -$253K | -454,026 | Closed |
|
|
30
Balyasny Asset Management
Chicago,
Illinois
| – | -$27.8K | -49,880 | Closed |
|
|
CFM
31
Catalyst Funds Management
Sydney NSW,
Australia
| – | -$446 | -800 | Closed |
|
TSBX Hedge Fund Activity: Q4 2024 in Review
28 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Turnstone Biologics (TSBX) for Q4 2024, worth a combined $5.51M — down 14% from $6.37M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TSBX positions and 3 closed out — a net gain of 4 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $33.3K. The largest seller was ExodusPoint Capital Management, exiting entirely with an estimated $253K sold.
- 28 institutional investors held Turnstone Biologics (TSBX) as of Q4 2024, up from 24 in Q3 2024.
- Funds reported $5.51M of Turnstone Biologics stock for Q4 2024, down 14% quarter-over-quarter.
- 7 funds opened new Turnstone Biologics positions in Q4 2024 and 3 closed out, a net change of +4 holders.
- The largest Turnstone Biologics buyer in Q4 2024 was Susquehanna International Group, an estimated $33.3K added.
- The largest Turnstone Biologics seller in Q4 2024 was ExodusPoint Capital Management, an estimated $253K sold.
Based on aggregated 13F filings for Q4 2024.